Year: 2025

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a summary of recent business highlights. Upstream is developing verekitug, the only monoclonal antibody currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, in multiple severe respiratory...

CHICAGO, March 12, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the fourth quarter and year ended December 31, 2024. Peter Sack, Co-Chief Executive Officer, noted, “Since establishing the Chicago Atlantic platform in 2019, we have maintained a disciplined underwriting process that reflects the core tenets of successful direct lending. We focus on strong operators, the right states, cash flow, leverage, and collateral to manage downside risk and protect principal. This consistent process has worked extremely well for us as we are the largest platform focused on cannabis, and the third best exchange-listed mortgage REIT on a total return basis across all sectors of the financial...

— Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million — — Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlining, Prudent Cash Management, and Growing Global Momentum of VASCEPA®/VAZKEPA® (icosapent ethyl) Franchise — — Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing — — Company to Host Conference Call Today at 8:00 a.m. EDT — DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth quarter and recent operational highlights. “Since taking on the role of CEO...

Management to host investor conference call today, March 12th, at 8:30am ET MIAMI, March 12, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights:Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approval Announced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures Established headquarters in Miami, Florida, to optimally support...

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment. Green continued, “We are encouraged by the strong market reception of our new products by prominent academic institutions, contract research organizations and biopharma customers. In particular, we...

LONDON, March 12, 2025 (GLOBE NEWSWIRE) — Fourth Quarter Financial HighlightsOn March 12, 2025, the Board of Navigator Holdings Ltd. (NYSE: NVGS) (“Navigator Holdings,” “Navigator Gas,” “our,” “we,” “us” or the “Company”) declared a cash dividend of $0.05 per share for the quarter ended December 31, 2024, (the “Dividend”) under the Company’s Return of Capital policy, payable on April 3, 2025 to all shareholders of record as of the close of business U.S. Eastern Time on March 23, 2025. Also as part of the Company’s Return of Capital policy for the quarter ended December 31, 2024, the Company expects to repurchase approximately $1.9 million of its common stock between March 16, 2025, and March 31, 2025, subject to operating needs, market conditions, legal requirements, stock price and other circumstances,...

GREAT NECK, N.Y., March 12, 2025 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the “Company”) announced today that net income for the year ended December 31, 2024 was approximately $5,591,000, or $0.49 per share (based on approximately 11.4 million weighted-average outstanding common shares), versus approximately $5,476,000, or $0.48 per share (based on approximately 11.5 million weighted-average outstanding common shares) for the year ended December 31, 2023, an increase of $115,000, or 2.1%. This increase is primarily attributable to a decrease in interest expense, partially offset by a decrease in origination fees. Total revenue for the year ended December 31, 2024, was approximately $9,689,000, compared to approximately $9,796,000 for the year ended December 31, 2023, a decrease of $107,000, or 1.1%. The...

VEON to release 4Q 2024 trading update on 20 March 2025 Dubai, 12 March 2025 – VEON Ltd. (NASDAQ: VEON), a global digital operator, today confirms that the Group will release its selected financial and operating results for the fourth quarter and full year ended 31 December 2024, at or around 10:00 GST (2:00 EST) on 20 March 2025. VEON will also host a results conference call with senior management at 16:00 GST (8:00 EST) on the same day. 4Q24 results conference call To register and access the event, please click here or copy and paste this link to the address bar of your browser: https://veon-q4-2024-trading-update.open-exchange.net/. Once registered, you will receive registration confirmation on the email address mentioned during registration with the link to access the webcast and dial-in details to listen to the conference call over...

CHICAGO, March 12, 2025 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats” or “we”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today provided financial results for the full year and fourth quarter ended December 31, 2024. “As we reflect on 2024, we are encouraged by the performance of our investments that continue to drive differentiation and efficiency in our marketplace,” said Stan Chia, Vivid Seats CEO. “In 2024 we harnessed synergies from Vegas.com, innovated with Game Center, and added robust seller functionality with Skybox Drive. As we look forward, we remain confident in the long-term tailwinds driving North American live events and will continue making investments...

Revenue up 2.2% to $2.1 billion, including organic growth of 1.6% Net income of $43.6 million and earnings per diluted share of $0.69, versus $44.7 million and $0.70 in the prior year, respectively Adjusted net income of $55.3 million and adjusted earnings per diluted share of $0.87, as compared to $54.8 million, or $0.86 in the prior year, respectively Adjusted EBITDA of $120.6 million versus $116.7 million in the prior year Increases lower end of fiscal 2025 adjusted EPS outlook by $0.05, now projecting full year adjusted EPS between $3.65 to $3.80 (1)NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility solutions, today announced financial results for the first quarter of fiscal 2025. “ABM’s first quarter performance reflects a continuation of the key trends we saw in 2024, including...